AKT1 and cancer: Studies on the PI3K/AKT signalling pathway as a targeted cancer therapy have been performed for more than a decade, and the Federal Drug Administration (FDA) has approved p110delta inhibitors for the treatment of certain types of lymphoma, providing hope for cancer treatment.